Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1299

1.

First-in-Human Phase 1 Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients With Relapsed and Refractory Multiple Myeloma.

Vij R, Nath R, Afar DEH, Mateos MV, Berdeja JG, Raab MS, Guenther A, Martinez-Lopez J, Jakubowiak AJ, Leleu X, Weisel K, Wong S, Gulbranson S, Sheridan JP, Reddy A, Paiva B, Singhal A, San-Miguel JF, Moreau P.

Clin Cancer Res. 2020 Jan 22. pii: clincanres.1431.2019. doi: 10.1158/1078-0432.CCR-19-1431. [Epub ahead of print]

PMID:
31969330
2.

Stick-slip dynamics of cell adhesion triggers spontaneous symmetry breaking and directional migration of mesenchymal cells on one-dimensional lines.

Hennig K, Wang I, Moreau P, Valon L, DeBeco S, Coppey M, Miroshnikova YA, Albiges-Rizo C, Favard C, Voituriez R, Balland M.

Sci Adv. 2020 Jan 3;6(1):eaau5670. doi: 10.1126/sciadv.aau5670. eCollection 2020 Jan.

3.

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.

Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, Krönke J, Facon T, Salnikov AV, Lesley R, Beutner K, Kalabus J, Rasmussen E, Riemann K, Minella AC, Munzert G, Einsele H.

J Clin Oncol. 2020 Jan 2:JCO1902657. doi: 10.1200/JCO.19.02657. [Epub ahead of print]

PMID:
31895611
4.

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD.

Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30788-0. doi: 10.1016/S1470-2045(19)30788-0. [Epub ahead of print]

PMID:
31859245
5.

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design.

Moreau P, Dimopoulos MA, Yong K, Mikhael J, Risse ML, Asset G, Martin T.

Future Oncol. 2020 Jan;16(2):4347-4358. doi: 10.2217/fon-2019-0431. Epub 2019 Dec 13.

6.

Functionalization of 9-thioxanthone at the 1-position: From arylamino derivatives to [1]benzo(thio)pyrano[4,3,2-de]benzothieno[2,3-b]quinolines of biological interest.

Mokhtari Brikci-Nigassa N, Nauton L, Moreau P, Mongin O, Duval RE, Picot L, Thiéry V, Souab M, Baratte B, Ruchaud S, Bach S, Le Guevel R, Bentabed-Ababsa G, Erb W, Roisnel T, Dorcet V, Mongin F.

Bioorg Chem. 2020 Jan;94:103347. doi: 10.1016/j.bioorg.2019.103347. Epub 2019 Oct 10.

PMID:
31810757
7.

Pyridin-2(1H)one derivatives: A possible new class of therapeutics for mechanical allodynia.

Visseq A, Descheemaeker A, Pinto-Pardo N, Nauton L, Théry V, Giraud F, Abrunhosa-Thomas I, Artola A, Anizon F, Dallel R, Moreau P.

Eur J Med Chem. 2020 Feb 1;187:111917. doi: 10.1016/j.ejmech.2019.111917. Epub 2019 Nov 26.

PMID:
31806536
8.

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group.

Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Erratum in: Lancet. 2019 Dec 7;394(10214):2072.

PMID:
31735560
9.

Insights on Multiple Myeloma Treatment Strategies.

Mateos MV, Ludwig H, Bazarbachi A, Beksac M, Bladé J, Boccadoro M, Cavo M, Delforge M, Dimopoulos MA, Facon T, Geraldes C, Goldschmidt H, Hájek R, Hansson M, Jamroziak K, Leiba M, Masszi T, Mendeleeva L, O'Dwyer M, Plesner T, San-Miguel JF, Straka C, van de Donk NWCJ, Yong K, Zver S, Moreau P, Sonneveld P.

Hemasphere. 2018 Dec 27;3(1):e163. doi: 10.1097/HS9.0000000000000163. eCollection 2019 Feb. Review.

10.

Twin-beam sub-shot-noise raster-scanning microscope.

Sabines-Chesterking J, McMillan AR, Moreau PA, Joshi SK, Knauer S, Johnston E, Rarity JG, Matthews JCF.

Opt Express. 2019 Oct 14;27(21):30810-30818. doi: 10.1364/OE.27.030810.

PMID:
31684324
11.

Good clinical practice recommendations for the use of PET/CT in oncology.

Salaün PY, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, Coriat R, Hindie E, Taieb D, Tabarin A, Girard A, Grellier JF, Brenot-Rossi I, Groheux D, Rousseau C, Deandreis D, Alberini JL, Bodet-Milin C, Itti E, Casasnovas O, Kraeber-Bodere F, Moreau P, Philip A, Balleyguier C, Luciani A, Cachin F.

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):28-50. doi: 10.1007/s00259-019-04553-8. Epub 2019 Oct 21.

PMID:
31637482
12.

Molecular Surveillance of EHV-1 Strains Circulating in France during and after the Major 2009 Outbreak in Normandy Involving Respiratory Infection, Neurological Disorder, and Abortion.

Sutton G, Garvey M, Cullinane A, Jourdan M, Fortier C, Moreau P, Foursin M, Gryspeerdt A, Maisonnier V, Marcillaud-Pitel C, Legrand L, Paillot R, Pronost S.

Viruses. 2019 Oct 4;11(10). pii: E916. doi: 10.3390/v11100916.

13.

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma.

Benaniba L, Tessoulin B, Trudel S, Pellat-Deceunynck C, Amiot M, Minvielle S, Gourraud PA, de Visme S, Maisonneuve H, Lok A, Le Gouill S, Moreau P, Touzeau C.

BMC Cancer. 2019 Aug 29;19(1):855. doi: 10.1186/s12885-019-6080-8.

14.

Biochemical Characterization of the α-l-Rhamnosidase DtRha from Dictyoglomus thermophilum: Application to the Selective Derhamnosylation of Natural Flavonoids.

Guillotin L, Kim H, Traore Y, Moreau P, Lafite P, Coquoin V, Nuccio S, de Vaumas R, Daniellou R.

ACS Omega. 2019 Jan 24;4(1):1916-1922. doi: 10.1021/acsomega.8b03186. eCollection 2019 Jan 31.

15.

Phylogenetic and distributional data on boletoid fungi (Boletaceae) in Cyprus and description of a new sampling methodology.

Loizides M, Bellanger JM, Assyov B, Moreau PA, Richard F.

Data Brief. 2019 Jun 11;25:104115. doi: 10.1016/j.dib.2019.104115. eCollection 2019 Aug.

16.

Genomic landscape and chronological reconstruction of driver events in multiple myeloma.

Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, Mitchell TJ, Fullam A, Gonzalez S, Szalat R, Abascal F, Rodriguez-Martin B, Samur MK, Glodzik D, Roncador M, Fulciniti M, Tai YT, Minvielle S, Magrangeas F, Moreau P, Corradini P, Anderson KC, Tubio JMC, Wedge DC, Gerstung M, Avet-Loiseau H, Munshi N, Campbell PJ.

Nat Commun. 2019 Aug 23;10(1):3835. doi: 10.1038/s41467-019-11680-1.

17.

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.

Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, Miguel JFS, Einsele H.

Haematologica. 2019 Dec;104(12):2358-2360. doi: 10.3324/haematol.2019.224204. Epub 2019 Aug 22.

18.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S.

N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.

PMID:
31433920
19.

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J.

Leukemia. 2020 Jan;34(1):224-233. doi: 10.1038/s41375-019-0539-0. Epub 2019 Aug 19.

PMID:
31427722
20.

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective.

Trudel S, Moreau P, Touzeau C.

Onco Targets Ther. 2019 Jul 18;12:5813-5822. doi: 10.2147/OTT.S174640. eCollection 2019. Review.

21.

Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.

Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH.

Int J Hematol. 2019 Oct;110(4):466-473. doi: 10.1007/s12185-019-02704-z. Epub 2019 Aug 6.

PMID:
31388932
22.

The Autoimmune Regulator (Aire) transactivates HLA-G gene expression in thymic epithelial cells.

Melo-Lima BL, Poras I, Passos GA, Carosella ED, Donadi EA, Moreau P.

Immunology. 2019 Oct;158(2):121-135. doi: 10.1111/imm.13099. Epub 2019 Aug 19.

PMID:
31322727
23.

Phase and amplitude imaging with quantum correlations through Fourier Ptychography.

Aidukas T, Konda PC, Harvey AR, Padgett MJ, Moreau PA.

Sci Rep. 2019 Jul 18;9(1):10445. doi: 10.1038/s41598-019-46273-x.

24.

Imaging Bell-type nonlocal behavior.

Moreau PA, Toninelli E, Gregory T, Aspden RS, Morris PA, Padgett MJ.

Sci Adv. 2019 Jul 12;5(7):eaaw2563. doi: 10.1126/sciadv.aaw2563. eCollection 2019 Jul.

25.

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.

Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T, Clemens PL, Luo M, Liu K, San-Miguel J.

Blood. 2019 Aug 22;134(8):668-677. doi: 10.1182/blood.2019000667. Epub 2019 Jul 3.

26.

Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis.

Morvan L, Carlier T, Jamet B, Bailly C, Bodet-Milin C, Moreau P, Kraeber-Bodéré F, Mateus D.

Int J Comput Assist Radiol Surg. 2020 Jan;15(1):129-139. doi: 10.1007/s11548-019-02015-y. Epub 2019 Jun 29. Review.

PMID:
31256359
27.

High level of soluble human leukocyte antigen (HLA)-G at beginning of pregnancy as predictor of risk of malaria during infancy.

d'Almeida TC, Sadissou I, Sagbohan M, Milet J, Avokpaho E, Gineau L, Sabbagh A, Moutairou K, Donadi EA, Favier B, Pennetier C, Baldet T, Moiroux N, Carosella E, Moreau P, Rouas-Freiss N, Cottrell G, Courtin D, Garcia A.

Sci Rep. 2019 Jun 24;9(1):9160. doi: 10.1038/s41598-019-45688-w.

28.

Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Hari P, Paba-Prada CE, Voorhees PM, Frye J, Chang YL, Moreau P, Zonder J, Boccia R, Shain KH.

Leuk Res. 2019 Aug;83:106172. doi: 10.1016/j.leukres.2019.106172. Epub 2019 Jun 17.

PMID:
31229804
29.

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.

Boyle EM, Leleu X, Petillon MO, Karlin L, Doyen C, Demarquette H, Royer B, Macro M, Moreau P, Fostier K, Marie-Lorraine C, Zarnitsky C, Perrot A, Herbaux C, Poulain S, Manier S, Beauvais D, Walker BA, Wardell CP, Vincent L, Frenzel L, Caillon H, Susanna S, Dejoie T, Avet-Loiseau H, Mohty M, Facon T; IFM2014-04 investigators.

Br J Haematol. 2019 Nov;187(3):319-327. doi: 10.1111/bjh.16059. Epub 2019 Jun 19.

PMID:
31218679
30.

[Alcohol consumption and head and neck cancer].

Goffinet M, Ransy P, Bouchain O, Lefebvre P, Moreau P.

Rev Med Liege. 2019 May;74(5-6):349-353. French.

31.

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma.

Adamia S, Abiatari I, Amin SB, Fulciniti M, Minvielle S, Li C, Moreau P, Avet-Loiseau H, Munshi NC, Anderson KC.

Leukemia. 2020 Jan;34(1):167-179. doi: 10.1038/s41375-019-0498-5. Epub 2019 Jun 10.

32.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P.

Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3. Erratum in: Lancet. 2019 Jun 14;:.

PMID:
31171419
33.

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.

Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1. doi: 10.1016/j.clml.2019.04.018. Epub 2019 May 2.

34.

Correction of adult spinal deformity with a minimally invasive fusionless bipolar construct: Preliminary results.

Wolff S, Habboubi K, Sebaaly A, Moreau PE, Miladi L, Riouallon G.

Orthop Traumatol Surg Res. 2019 Oct;105(6):1149-1155. doi: 10.1016/j.otsr.2019.02.015. Epub 2019 May 29. Review.

PMID:
31153861
35.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators.

N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.

PMID:
31141632
36.

Early warning sensors for monitoring mercury in water.

Pinaeva U, Lairez D, Oral O, Faber A, Clochard MC, Wade TL, Moreau P, Ghestem JP, Vivier M, Ammor S, Nocua R, Soulé A.

J Hazard Mater. 2019 Aug 15;376:37-47. doi: 10.1016/j.jhazmat.2019.05.023. Epub 2019 May 14.

PMID:
31121451
37.

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P.

Blood. 2019 Aug 1;134(5):421-431. doi: 10.1182/blood.2019000722. Epub 2019 May 21.

38.

Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study).

Moreau P, Kumar S, Boccia R, Iida S, Goldschmidt H, Cocks K, Trigg A, Zahlten-Kumeli A, Yucel E, Panjabi SS, Dimopoulos M.

Leukemia. 2019 Dec;33(12):2934-2946. doi: 10.1038/s41375-019-0480-2. Epub 2019 May 15.

PMID:
31092895
39.

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.

Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Fontan J, Voillat L, Demarquette H, Collet P, Rodon P, Sohn C, Lifermann F, Orsini-Piocelle F, Richez V, Mohty M, Macro M, Minvielle S, Moreau P, Leleu X, Facon T, Attal M, Avet-Loiseau H, Corre J.

J Clin Oncol. 2019 Jul 1;37(19):1657-1665. doi: 10.1200/JCO.18.00776. Epub 2019 May 15.

40.

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.

Mateos MV, Orlowski RZ, Ocio EM, Rodríguez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel J.

Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15. No abstract available.

PMID:
31090915
41.

Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.

Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, Chevallier P, Vigouroux S, Peterlin P, Garnier A, Rubio MT, Huynh A, Milpied N, Moreau P, Gaugler B, Yakoub-Agha I, Mohty M.

Bone Marrow Transplant. 2019 Nov;54(11):1815-1826. doi: 10.1038/s41409-019-0536-y. Epub 2019 May 14.

PMID:
31089280
42.

HLA-G expression during hookworm infection in pregnant women.

Avokpaho E, d'Almeida TC, Sadissou I, Tokplonou L, Adamou R, Sonon P, Milet J, Cottrell G, Mondière A, Massougbodji A, Moutairou K, Donadi EA, Teixeira Mendes Junior C, Favier B, Carosella E, Moreau P, Rouas-Freiss N, Garcia A, Courtin D.

Acta Trop. 2019 Aug;196:52-59. doi: 10.1016/j.actatropica.2019.04.026. Epub 2019 May 9.

PMID:
31078470
43.

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Leleu X, Fouquet G, Richez V, Guidez S, Duhamel A, Machuron F, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Roussel M, Jaccard A, Pétillon MO, Belhadj-Merzoug K, Lepeu G, Chrétien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Attal M, Moreau P, Avet-Loiseau H, Hulin C, Facon T.

Clin Cancer Res. 2019 Jul 15;25(14):4224-4230. doi: 10.1158/1078-0432.CCR-18-3642. Epub 2019 May 3.

PMID:
31053600
44.

Theoretical assessment of the OTDR detector noise on plasma current measurement in tokamaks.

Motuz R, Leysen W, Moreau P, Gusarov A, Drexler P, Wuilpart M.

Appl Opt. 2019 Apr 10;58(11):2795-2802. doi: 10.1364/AO.58.002795.

PMID:
31044879
45.

FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Cytokine. 2019 Aug;120:85-87. doi: 10.1016/j.cyto.2019.04.015. Epub 2019 Apr 28.

PMID:
31035172
46.

Interest of Pet Imaging in Multiple Myeloma.

Jamet B, Bailly C, Carlier T, Touzeau C, Nanni C, Zamagni E, Barré L, Michaud AV, Chérel M, Moreau P, Bodet-Milin C, Kraeber-Bodéré F.

Front Med (Lausanne). 2019 Apr 9;6:69. doi: 10.3389/fmed.2019.00069. eCollection 2019. Review.

47.

New insights in the treatment of patients with solitary bone plasmacytoma.

Mheidly K, Lamy De La Chapelle T, Hunault M, Benboubker L, Benchalal M, Moreau P, Baugier de Materre A, Decaux O, Laribi K.

Leuk Lymphoma. 2019 Nov;60(11):2810-2813. doi: 10.1080/10428194.2019.1605067. Epub 2019 Apr 25. No abstract available.

PMID:
31020888
48.

Thermomechanical Polymer Binder Reactivity with Positive Active Materials for Li Metal Polymer and Li-Ion Batteries: An XPS and XPS Imaging Study.

Grissa R, Abramova A, Tambio SJ, Lecuyer M, Deschamps M, Fernandez V, Greneche JM, Guyomard D, Lestriez B, Moreau P.

ACS Appl Mater Interfaces. 2019 May 22;11(20):18368-18376. doi: 10.1021/acsami.9b01761. Epub 2019 May 8.

PMID:
31020833
49.

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Pertesi M, Vallée M, Wei X, Revuelta MV, Galia P, Demangel D, Oliver J, Foll M, Chen S, Perrial E, Garderet L, Corre J, Leleu X, Boyle EM, Decaux O, Rodon P, Kolb B, Slama B, Mineur P, Voog E, Le Bris C, Fontan J, Maigre M, Beaumont M, Azais I, Sobol H, Vignon M, Royer B, Perrot A, Fuzibet JG, Dorvaux V, Anglaret B, Cony-Makhoul P, Berthou C, Desquesnes F, Pegourie B, Leyvraz S, Mosser L, Frenkiel N, Augeul-Meunier K, Leduc I, Leyronnas C, Voillat L, Casassus P, Mathiot C, Cheron N, Paubelle E, Moreau P, Bignon YJ, Joly B, Bourquard P, Caillot D, Naman H, Rigaudeau S, Marit G, Macro M, Lambrecht I, Cliquennois M, Vincent L, Helias P, Avet-Loiseau H, Moreno V, Reis RM, Varkonyi J, Kruszewski M, Vangsted AJ, Jurczyszyn A, Zaucha JM, Sainz J, Krawczyk-Kulis M, Wątek M, Pelosini M, Iskierka-Jażdżewska E, Grząśko N, Martinez-Lopez J, Jerez A, Campa D, Buda G, Lesueur F, Dudziński M, García-Sanz R, Nagler A, Rymko M, Jamroziak K, Butrym A, Canzian F, Obazee O, Nilsson B, Klein RJ, Lipkin SM, McKay JD, Dumontet C.

Leukemia. 2019 Sep;33(9):2324-2330. doi: 10.1038/s41375-019-0452-6. Epub 2019 Apr 9. No abstract available.

50.

Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies.

Zeinyeh W, Esvan YJ, Josselin B, Baratte B, Bach S, Nauton L, Théry V, Ruchaud S, Anizon F, Giraud F, Moreau P.

Bioorg Med Chem. 2019 May 15;27(10):2083-2089. doi: 10.1016/j.bmc.2019.04.005. Epub 2019 Apr 4.

PMID:
30967303

Supplemental Content

Loading ...
Support Center